| Gene Symbol | amyloid |
| Foundational biomarker | Positive amyloid PET defines the "A" in AT(N) |
| Therapeutic eligibility | Required for anti-amyloid therapy (lecanemab, donanemab) selection |
| Prognostic value | Positive amyloid predicts future cognitive decline |
| Staging | Higher amyloid burden correlates with disease stage |
| Isotope | Fluorine-18 (18F), half-life ~110 minutes |
| Binding target | Fibrillar amyloid-beta plaques |
| Binding mechanism | Thioflavin-T derivative that intercalates into β-sheet structures of aggregated Aβ |
| Regional uptake | Preferential binding to cortical regions affected in AD |
| Advantage | Longer half-life allows centralized production and distribution to imaging centers |
| Limitation | Requires on-site cyclotron due to short half-life of 11C[@klunk2015] |
| Clinical approval | Indicated for patients with cognitive impairment undergoing evaluation for AD or other causes of dementia |
| Standard uptake value ratio (SUVR) | Typically measured 50-70 minutes post-injection[@wong2010][@navitsky2018] |
| Structure | 18F-labeled thioflavin-T analog |
| Binding characteristics | High affinity for fibrillar Aβ plaques |
| Clinical use | Approved for visual read of amyloid plaques in living brain |
| Associated Diseases | Alzheimer's disease, cognitive deficits, neurodegeneration |
| KG Connections | 20 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!